Understand the Chance for Protection Against Hepatitis A Virus (HAV)*
IN 3 CLINICAL STUDIES, 80% TO 98% OF VACCINEES HAD SEROCONVERTED BY DAY 15 AFTER A SINGLE DOSE OF HAVRIX1
IN 2 CLINICAL TRIALS, 100% OF VACCINEES WERE SEROPOSITIVE 1 MONTH FOLLOWING A 6-MONTH BOOSTER OF HAVRIX1
In a subset of vaccinees (n=89), a single dose of HAVRIX 1440 EL.U. elicited specific anti-HAV neutralizing antibodies in more than 94% of vaccinees when measured 1 month after vaccination. These neutralizing antibodies persisted until Month 6. One hundred percent of vaccinees had neutralizing antibodies when measured after a booster dose given at month 6.1
HAVRIX 1440 EL.U. is only indicated for ages 19 and older. Some study subjects were under age 19.